All Stories

  1. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay

    Article • Current Drug Targets, December 2020, Bentham Science Publishers

    Dr Matteo Santoni, Liang Cheng

  2. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma

    Article • Current Drug Targets, October 2020, Bentham Science Publishers

    Liang Cheng

  3. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Dr Matteo Santoni, Liang Cheng

  4. Liquid biopsy in the clinical management of bladder cancer: current status and future developments

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Dr Matteo Santoni, Liang Cheng

  5. Liquid biopsies in urological cancers: what we need to know before starting using them

    Article • Expert Review of Molecular Diagnostics, September 2019, Taylor & Francis

    Liang Cheng

  6. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies

    Article • Expert Review of Molecular Diagnostics, September 2019, Taylor & Francis

    Dr Matteo Santoni, Liang Cheng

  7. Dissecting the molecular landscape of pancreatic cancer: towards a precision medicine approach

    Article • Expert Review of Precision Medicine and Drug Development, April 2019, Taylor & Francis

    Liang Cheng

  8. Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy

    Article • Expert Review of Molecular Diagnostics, November 2018, Taylor & Francis

    Liang Cheng

  9. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma

    Article • Expert Review of Anticancer Therapy, November 2018, Taylor & Francis

    Liang Cheng

  10. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples

    Article • Cancer Cytopathology, October 2018, Wiley

    Liang Cheng

  11. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma

    Article • International Journal of Cancer, September 2018, Wiley

    Liang Cheng

  12. Inherited forms of bladder cancer: a review of lynch syndrome and other inherited conditions

    Article • Future Oncology, January 2018, Future Medicine

    Liang Cheng

  13. Classical gonadoblastoma: its relationship to the ‘dissecting’ variant and undifferentiated gonadal tissue

    Article • Histopathology, November 2017, Wiley

    Liang Cheng

  14. Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases

    Article • Histopathology, October 2017, Wiley

    Liang Cheng

  15. Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

    Article • Current Drug Metabolism, October 2017, Bentham Science Publishers

    Liang Cheng

  16. Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice

    Article • Current Drug Metabolism, October 2017, Bentham Science Publishers

    Liang Cheng

  17. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives

    Article • Current Drug Metabolism, October 2017, Bentham Science Publishers

    Liang Cheng

  18. Urinary Biomarkers for Prostate Cancer

    Article • Current Drug Metabolism, October 2017, Bentham Science Publishers

    Liang Cheng

  19. Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity

    Article • Molecular Carcinogenesis, August 2017, Wiley

    Liang Cheng, Dr Shaobo Zhang

  20. Pathology and molecular updates in tumors of the prostate: towards a personalized approach

    Article • Expert Review of Molecular Diagnostics, June 2017, Taylor & Francis

    Liang Cheng

  21. Immunotherapy in genitourinary cancers: where are we going?

    Article • Expert Review of Precision Medicine and Drug Development, March 2017, Taylor & Francis

    Liang Cheng

  22. Fluorescencein situhybridization in surgical pathology: principles and applications

    Article • The Journal of Pathology Clinical Research, February 2017, Wiley

    Dr Shaobo Zhang, Liang Cheng

  23. Activity of Chemokines in Prostate and Renal Tumors and their Potential Role as Future Therapeutic Targets

    Article • Future Oncology, February 2017, Taylor & Francis

    Liang Cheng

  24. Evidence of a dual histogenetic pathway of sacrococcygeal teratomas

    Article • Histopathology, October 2016, Wiley

    Liang Cheng

  25. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 – kidney cancer

    Article • Future Oncology, September 2016, Future Medicine

    Dr Sebastiano Buti, Liang Cheng

  26. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 – prostate and bladder cancer

    Article • Future Oncology, September 2016, Future Medicine

    Dr Sebastiano Buti, Liang Cheng

  27. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change

    Article • Histopathology, February 2016, Wiley

    Liang Cheng

  28. Role of STAT3 pathway in genitourinary tumors

    Article • Future Science OA, November 2015, Future Science

    Dr Matteo Santoni, Liang Cheng

  29. Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma

    Article • Histopathology, October 2015, Wiley

    Liang Cheng

  30. Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus

    Article • Future Oncology, October 2015, Future Medicine

    Liang Cheng

  31. Incidental prostate cancer in Asian men: High prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy

    Article • The Prostate, February 2015, Wiley

    Liang Cheng

  32. Molecular Foundations for Personalized Therapy in Prostate Cancer

    Article • Current Drug Targets, February 2015, Bentham Science Publishers

    Liang Cheng

  33. Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescencein-situhybridization for the detection of anaplastic lymphoma kinase alterations

    Article • Histopathology, January 2015, Wiley

    Liang Cheng

  34. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma

    Article • Molecular Carcinogenesis, April 2014, Wiley

    Liang Cheng